Chemed Corporation

NYSE:CHE

Medical - Care Facilities

Healthcare
$546.72 +1.13%

+$4.91 today

Market cap
$7.12B
Beta
0.54
P/E (TTM)
23.2
EPS (TTM)
$19.00
Dividend yield
0.54%
52W Low $365.21High $562.77

Volume 0.17M

Average 0.25M

CHE Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Chemed CorporationNYSE: CHE

Research & Development · Q2 FY2026 · quarter ended Jun 2026

Research & development remains negative

Q2 FY2026 research & development was $0, compared with $0 a year earlier. Trailing-twelve-month research & development was $0.

Context

  • Research & development amounted to 0.0% of revenue in FY2025, unchanged from a year earlier.
  • Research & development increased in 0 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly research & development holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
$0— QoQ
Last fiscal yearDec 2025
$0— YoY
LTMJun 2026
$0— YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
0 USD
Year-over-year change
—

Research & Development vs competitors

How CHE compares with its peers on the latest reported figures

  • CHE's LTM Jun 2026 research & development of $0 is the highest of the 5 companies compared; the peer median is $0.
  • Research & development amounts to 0.0% of revenue for CHE, versus a peer median of 0.0%.
CHE Competitors Peer median
Research & Development for CHE and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CHEChemed CorporationLTM Jun 2026$0 ——0.0%
OPCHOption Care Health, Inc.LTM Sep 2026$0 ——0.0%
AVAHAveanna Healthcare Holdings Inc.LTM Oct 2026$0 ——0.0%
ADUSAddus HomeCare CorporationLTM Jun 2026$0 ——0.0%
PNTGThe Pennant Group, Inc.LTM Mar 2026$0 ——0.0%
Peer median (excluding CHE) $0——0.0%

Competitors are the stored peer set for CHE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue2.14B2.13B2.26B2.43B2.53B
Cost of Revenue1.37B1.37B1.47B1.58B1.77B
Gross Profit769.8M765.09M798.82M854.35M758.34M
Gross Margin36.0%35.8%35.3%35.1%30.0%
Research & Development00000
Selling, General & Admin366.73M358.73M395.12M424.36M417.19M
Operating Expenses426.77M421.59M458.25M487.86M417.19M
Depreciation & Amortization59.05M59.17M60.87M63.05M64.84M
EBITDA411.23M393.44M414.34M464.29M422.37M
EBITDA Margin19.2%18.4%18.3%19.1%16.7%
Operating Income343.04M343.5M340.57M366.49M338.25M
Operating Margin16.0%16.1%15.0%15.1%13.4%
Interest Income377K355K6.27M14.61M8.75M
Interest Expense1.87M4.58M3.11M1.78M1.75M
Other Income / Expenses7.28M(13.82M)9.8M32.97M17.53M
Income Before Tax350.31M329.68M350.37M399.47M355.78M
Pre-Tax Margin16.4%15.4%15.5%16.4%14.1%
Income Tax Expense81.76M80.06M77.86M97.47M90.54M
Net Income268.55M249.62M272.51M302M265.24M
Net Margin12.6%11.7%12.0%12.4%10.5%
EPS (Basic)17.1416.7218.1120.1018.42
EPS (Diluted)16.8516.5317.9319.8918.42
Weighted Avg Shares15.67M14.93M15.05M15.02M14.4M
Weighted Avg Shares (Diluted)15.94M15.1M15.2M15.19M14.4M

Chemed Corporation

NYSE:CHE

Intrinsic Alpha fair value

Locked

Current Price

$546.72

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.